We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

BellBrook Labs Introduces the Transcreener™ KINASE TR-FRET Assay

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BellBrook has introduced the Transcreener™ Assays which rely on homogenous immunodetection of nucleotides, which means robust, generic detection of entire families of drug targets. 

With the introduction of the Transcreener™ KINASE TR-FRET Assay, BellBrook is extending ADP detection beyond its original far-red FP format.

The Transcreener™ KINASE TR-FRET Assay is a fluorescence resonance energy transfer (TR-FRET) immunoassay for the detection of ADP.  It relies on a proprietary monoclonal antibody that differentiates ADP from ATP with high selectivity. 

The Transcreener™ KINASE TR-FRET Assay can be used for enzyme class that produces ADP, including protein, lipid or carbohydrate kinases, ATPases, DNA helicases, and carboxyltransferases.

Designed as a simple “mix and read” assay, it can provide a signal at low ATP conversion resulting in overall Z’> 0.6. The assay can accommodate from 1 µM to 100 µM ATP.